Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment